最新更新 :
28/04/2024
抗癫痫药   Phenobarbital sodium  
注射液
口服剂
溶液稳定性 混合物稳定性 影响稳定性的因素 兼容性 用药途径 引用文献 PDF
   化学式  

商品名   商品名     

商品名仅供参考, 药品所用的辅料可能依国家或厂商不同有所不同。

Carbital 巴西
Fenemal 瑞典
Fenobarb 印度
Fenobarbital 厄瓜多尔, 哥伦比亚, 阿根廷
Gardenal 印度, 委内瑞拉, 巴西, 摩洛哥, 法国, 突尼斯, 英国
Luminal 伊朗, 德国, 西班牙
Luminale 意大利
Luminalum 波兰
Phenobarbital sodium 加拿大, 英国
Sominaletta 埃及
引用文献   注射液   引用文献 : Phenobarbital sodium  
种类 出版物
58 文献 Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161.
201 文献 Thompson DF, Allen LV, Stiles ML.
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2530-2531.
226 文献 Walker SE, DeAngelis C, Iazzetta J.
Stability and compatibility of combinations of hydromorphone and a second drug.
Can J Hosp Pharm 1991 ; 44: 289-295.
266 文献 Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
300 文献 Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 文献 Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
349 文献 Nahata MC, Hipple TF, Strausbaugh SD.
Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection.
Am J Hosp Pharm 1986 ; 43: 384-385.
642 文献 Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA.
Norepinephrine stability in saline solutions.
Hosp Pharm 1988 ; 23: 44,49, 59.
660 文献 Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
921 文献 Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1057 文献 Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 文献 Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1412 文献 Brett A, Riggs RM, Webster AA, Benner KW.
Y-site stability of fosphenytoin and sodium phenobarbital.
Int J Pharm Compound 1999 ; 3: 64-66.
1415 文献 Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1625 文献 Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1802 文献 Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
1925 文献 Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1974 文献 Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171.
2090 文献 Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2262 文献 Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3379 文献 Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3408 文献 Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3501 实验室 Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics
Pfizer 2011
3525 实验室 Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012
3526 实验室 Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3531 实验室 Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3596 实验室 Chlorpromazine (Largactil®) - Summary of Product Characteristics
Sanofi 2014
3631 实验室 Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit
Aguettant 2016
3674 实验室 Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3676 实验室 Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit
Hospira 2014
4009 实验室
Droperidol - Résumé des Caractéristiques du Produit
Panpharma 2017
4419 文献 Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4435 文献 Hanifah S, Nugroho B.H, Chabib L.
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4543 文献 Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4700 实验室 Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics
AS Kalceks 2022
4742 文献 Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales